Head & Neck/Thyroid Cancers
Conference Coverage
When it comes to thyroid cancer follow-up, serum microRNA profiles have earned new respect
CHICAGO – Serum thyroglobulin is not the only sheriff in town for thyroid cancer follow-up.
Case Reports
Recurrent head and neck cancer presenting as a large retroperitoneal mass
Conference Coverage
Pembrolizumab plus SBRT shows promise for advanced solid tumors
Pembrolizumab immunotherapy with multi-site SBRT appears to be a safe and effective treatment in patients with advanced solid tumors.
Conference Coverage
New and improved classifiers may sharpen thyroid nodule diagnosis
VICTORIA, B.C. – The tests could improve preoperative assessment, even in histologic subsets that pose diagnostic challenges.
From the Journals
ASCO larynx-preservation guidelines reflect important practice changes
Larynx-preserving techniques do not compromise survival in patients with early-stage laryngeal cancers.
Case Reports
Management of tonsillar carcinoma with advanced radiation therapy and chemotherapy techniques
Conference Coverage
Cancer patients with TKI-induced hypothyroidism had better survival rates
When it comes to the adverse effects of tyrosine kinase inhibitors, hypothyroidism appears to have a bright side.
From the Journals
Papillary thyroid microcarcinoma: Is ‘less is more’ the right approach?
Expert questions whether current guidance favoring total thyroidectomy goes too far.
Conference Coverage
Keynote 040: Pembrolizumab misses efficacy endpoint in advanced HNSCC
MADRID – Median OS in the ITT population was 8.4 months in the pembrolizumab arm, vs. 7.1 months in the standard-of-care arm.
From the Journals
Liquid biopsy predicts checkpoint inhibitor response
The overall response rate to immune checkpoint inhibitors was 45% among cancer patients who had more than three variants of unknown significance...
Conference Coverage
Calcitonin-to-CEA ratio predicts medullary thyroid cancer survival
Can a ratio of serum calcitonin to carcinoembryonic antigen predict survival in patients with medullary thyroid cancer?